Suraksha Diagnostics – Competition To Intensify In Pathology: Systematix

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

We hosted the management of Suraksha Diagnostics Pvt. Ltd. at our virtual conference on the diagnostics industry. The company believes the diagnostic space presents exponential growth opportunities. However, in the near term, the management expects diagnostic companies focused on pathology to face heightened competitive pressures from organised peers, hospitals, pharmaceutical companies, start-ups and online aggregators.

Diagnostic companies focused on radiology would be better placed, as per the management’s view, given the high entry barriers there, and due to potential expansion in the array of tests prescribed in neurology.

Digital aggregators focused on the pathology pie do come with some brand equity and lower cost structures, but they still need to develop trust levels with the physician community, who may insist on reports from specific labs.

Currently, digital aggregators have negligible market share. The pathology industry in India is an aggregation of regional players and individual labs. We are yet to see a pan-India player in the true sense of it.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.